**Wednesday 10-28-15**

Live meeting + WebEx Meeting

Meeting called by: Becky Brtva

Note taker: Lori Jones

Type of meeting: Monthly meeting

Attendees: Becky Brtva, Lori Jones, Elizabeth Smith, Steve Dudley, Julie Ross, Elizabeth Smith, Tiffany Moody

WebEx Attendees: Tammy Droscha, Rosie Beard, Joanne Burbrink

**Biomerieux Vidas III Procalcitonin Presentation**

* Jerry Stalder, IA Specialist and Dennis Maxwell, Reagent Specialist had a short presentation and instrument demonstration

**OLD BUSINESS**

* **DBR status**
  + URINE CALCS (architect) – not yet assigned. Tentative go-live date in January 2016.
  + DI REPORTING (QLS) – Jan Edwards, working on a way to electronically validate high/diluted values from DI that report to SQ and QLS the same.
  + BFpH (Cobas b221) – waiting on SOP – should be submitted by the end of the week. Terry from CHS is now working on it. Do we want a separate SOP for body fluid ph, or should it be included in the Cobas SOP?
  + ABG (Cobas b221) – SOP is complete, will send out read and sign reminders.
  + FARZY MIQ PROJECT – We need to keep up with our DBR validations to make sure any DBR that affects you gets validated in a timely manner.
* **HCG RAM messages**
  + Standardization was not an option as there were too many differences between platforms. The Architect RAM has been corrected.
* **RANGES**
  + **CSFGL –** SOP revision – needs separate DBR – Lori Jones submitted the DBR (#17601) on 10-26-15. It has been assigned to Jan Edwards.
* **Lactic Acid**
  + QART has approved the change to sodium fluoride for LAC on the Architects. Wording needs to be drafted for client notifications so that they can work on getting supplies and education. Go live date is Jan 4. An abbreviated validation will need to be completed due to the change in specimen types.
  + Arterial LAC order codes have been activated for SVAN since they run it on their blood gas analyzer.
* **Urine reference ranges**
  + All random, timed and 24hr urine ranges have been evaluated, standardized and approved by QART. Jan Edwards is working on the DBR. Many of these changes have already been completed in SQ and CIS due to the urgent request of Community Health. Farzy is working on the validations; any validations that need to be completed will be communicated.
* **Architect ACETO**
  + New SOP needs to be written including the 3rd party reagent installation instructions. Target completion date is November 30. Assigned to Tammy Droscha.

**NEW BUSINESS/SUBMISSIONS**

* **HBL Chemisry analyzer standardization –** There is a proposal going to the board to purchase 3 Vitros 4600 from this year’s capital. They will go to Fishers, Jennings & Dunn. The Architect fromo Dunn will go to SVAN. More Vitros will be purchased in 2016 for other critical access sites. For immunoassay, the Access will be the platform at the critical access sites. We will have to buy 2 Access instruments.
* **PCT Discussion**
  + There is concern about the cost & if we can get enough orders to make it cost effective. We may start with just 3 sites: SVEV, SVIN & either SVAN (due to their higher volumes already) or Kokomo. We may be able to courier specimens from the other sites to the nearest site to decrease TAT.
* **Beta-hydroxybutyrate**
  + Acetest unavailable at the end of the year. We may want to stock up on Acetest to be to be able to run through Feb 2016.
  + BHB is much more sensitive and has more diagnostic benefits
  + Stanbio Information in the ChemBPT Projects folder
  + We are looking at having hand held meters at all HBL sites; as volumes and demand increase we will look at adding meters or moving to on board reagents.
  + Meeting with the rep in November
  + Lori will check to see if there are any other vendors available.
* **SUBGROUP REPORT** 
  + Benchmarking – Lori - Drug screen confirmation specimens – referral requests that we send 1 yellow top tube per drug. Specimens can be kept at room temp.
  + Abbott- Stacy is no longer with MACL. Tammy will be taking over the Abbott group (with help). The work on the SOPs vs the package insert & Farzy’s spreadsheet is not done. Tammy will work on assigning tests to each site. They also need a paper maintenance log for the Architect.
  + Siemens- Joanne Burbink will act as liason since there is no more ‘subgroup’. They will be transitioning to a Vitros in first quarter of 2016. They may also need to change to a new creatinine, AMM, PHOS reagent since their current reagent cannot be ordered after Dec 1. Or, should they stock up on the current reagent to try to get through to the Vitros?
  + Vitros – Tammy Droscha transition to Jama Patterson +1
  + Beckman – Elizabeth Smith – Water SOPs – CAP says we only have to collect monthly water cultures, but best practice is weekly. We will collect weekly. CAP says we only need to document the Ohms & our bacterial count. We are suggesting one log for both systems. GTT SOP – should we have one SOP for the instructions, collection & analysis? For now, Elizabeth will put the analytical part in the SOP.
* **SUBGROUP ASSIGNMENTS**
  + SOP review- each platform should be looking for discrepancies in the SOPs vs the package insert vs Farzy’s spreadsheet
  + QA document
    - Farzy is creating this document. As soon as she is completed and it is effective we can remove the information from each individual SOP.

**TECHNICAL DISCUSSION/MONTHLY SUBMISSIONS**

* **OPEN FLOOR**
  + **MedTox –** there is no storage or stability in the SOP. MedTox says to store refrigerated if not tested immediately. SOP just says to test immediately, so some sites have been rejecting add-on orders. We will be adding a section to the SOP saying stability is 20 or 30 min at room temp & 24 hours refrigerated. Tammy will work on this
* **Next meeting: November 18**